

Antimicrobial Resistance Surveillance Market by Solution (Kits, System, Surveillance Software, Service), Application (Clinical Diagnostics, Public Health Surveillance), End User (Hospitals, Clinics, Academic, Research Institutes) - Global Forecast to 2028

Market Report | 2023-09-19 | 200 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global antimicrobial resistance surveillance market is projected to reach USD 7.7 billion by 2028 from USD 5.9 billion in 2023, at a CAGR of 5.6% during the forecast period. The growth in this market is driven by factors such as the growing prevalence of infections caused by drug-resistance pathogens, innovations in diagnostic technologies, escalating threat of antimicrobial resistance, growing government initiatives to combat antimicrobial-resistance species, and emergence of multi-drug resistance due to drug abuse. On the other hand, factors such as high cost associated to antimicrobial resistance diagnostic systems and kits are limiting the growth of this market.

In 2023, the diagnostic kits segment is projected to account for the largest share of the antimicrobial resistance surveillance market

By solutions, the global antimicrobial resistance surveillance market has been segmented into diagnostic kits, diagnostic systems, surveillance software, and services. In 2023, the diagnostic kits segment is estimated to command the largest share of the global antimicrobial resistance surveillance market. The large share of this segment can primarily be attributed to the rising need for early detection and treatment, increasing demand for rapid diagnostics for antimicrobial resistance, and need of essential data for surveillance and tracking of antimicrobial resistance trends.

Clinical Diagnostics is projected to account for the largest share of the antimicrobial resistance surveillance market in 2023

By application, the global antimicrobial resistance surveillance market has been segmented into clinical diagnostics, public health

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

surveillance, and other applications . In 2023, the clinical diagnostics segment is projected to account for the largest share of the global antimicrobial resistance surveillance market. The growth in this segment can be attributed to factors such as increasing preference for better patient outcomes, and prevalence of antimicrobial resistance.

By end user, hospitals and clinics accounted for the largest share of the market

By end users, the global antimicrobial resistance surveillance market has been segmented into hospitals & clinics, research and academic institutes, and others. In 2023, the hospitals & clinics segment accounted for the largest share of the global antimicrobial resistance surveillance market. The large share of this segment can be attributed to the high patient density in hospitals and clinics, increasing nosocomial infections in hospitals, and to maintain the infection control protocols.

By region, North America is projected to account for the largest share of the market

By region the global antimicrobial resistance surveillance segmented into-North America, Europe, Asia Pacific, Latin America, and Middle East Africa. In 2023, North American antimicrobial resistance surveillance market is expected to account for the largest share of the global antimicrobial resistance surveillance market. This can be attributed to the presence of leading market players, highest prevalence of antimicrobial resistance, and strong regulatory environment.

Break of primary participants was as mentioned below:

-□By Company Type - Tier 1-40%, Tier 2-30%, and Tier 3-30%

-□By Designation - C-level-27%, Director-level-18%, Others-55%

-□By Region - North America-45%, Europe-15%, Asia Pacific-25%, and Middle East & Africa- 5%,ROW- 10%

Key players in the antimicrobial resistance surveillance Market

The prominent players in this market are Qiagen (Germany), Luminex Corporation (US), Roche Diagnostics (Switzerland), OpGen, Inc. (US), Lumed (US), Wolters Kluwer N.V. (US), Abbott Laboratories (US), Bruker (US), Merck KgaA (Germany), Bio-Rad (US), Danaher (US), Bioanalyse (Turkey), Biomerieux (France), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), BioSpace (US), Cepheid (US), Accelerate Diagnostics, Inc. (US), Liofilchem S.r.l. (Italy), and Alifax S.r.l. (Italy).

Research Coverage:

The report analyzes the antimicrobial resistance surveillance Market and aims at estimating the market size and future growth potential of this market based on various segments such as solution, application and end user. The report also includes a product portfolio matrix of various antimicrobial resistance surveillance products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, service offerings, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:

Analysis of key drivers (growing prevalence of infections caused by drug-resistance pathogens, innovations in diagnostic technologies), restraints (high cost of antimicrobial resistance diagnostic systems/ kits), opportunities (growth opportunities in emerging countries and awareness initiatives for antimicrobial resistance and its control) and challenges (complex regulatory framework) influencing the growth of antimicrobial resistance surveillance market.

-□Market Penetration: Comprehensive information on product portfolios offered by the top players in the global antimicrobial resistance surveillance Market. The report analyzes this market by solution, applications, and end user.

-□Service Enhancement/Innovation: Detailed insights on upcoming trends in the global antimicrobial resistance surveillance Market

-□Market Development: Comprehensive information on the lucrative emerging markets by solutions, applications, and end user.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

-□Market Diversification: Exhaustive information about new services or service enhancements, growing geographies, recent developments, and investments in the global antimicrobial resistance surveillance Market.

-□Competitive Assessment: In-depth assessment of market shares, growth strategies, product and service offerings, company evaluation quadrant, and capabilities of leading players in the global antimicrobial resistance surveillance Market.

Table of Contents:

1	INTRODUCTION	27
1.1	STUDY OBJECTIVES	27
1.2	MARKET DEFINITION	27
1.2.1	INCLUSIONS & EXCLUSIONS	27
1.3	MARKET SCOPE	28
1.3.1	MARKETS COVERED	28
1.3.2	YEARS CONSIDERED	28
1.4	CURRENCY	29
TABLE 1	STANDARD CURRENCY CONVERSION RATES	29
1.5	LIMITATIONS	29
1.6	STAKEHOLDERS	29
1.7	RECESSION IMPACT ON ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET	30
2	RESEARCH METHODOLOGY	31
2.1	RESEARCH APPROACH	31
FIGURE 1	RESEARCH DESIGN	31
2.1.1	SECONDARY RESEARCH	31
2.1.1.1	Key data from secondary sources	32
2.1.2	PRIMARY DATA	33
FIGURE 2	PRIMARY SOURCES	33
2.1.2.1	Key data from primary sources	34
2.1.2.2	Insights from primary experts	34
FIGURE 3	BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION	35
2.2	MARKET SIZE ESTIMATION	35
FIGURE 4	MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS	36
FIGURE 5	BOTTOM-UP APPROACH	37
FIGURE 6	CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET (2023-2028)	38
FIGURE 7	CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS	38
2.3	APPROACH USED TO DETERMINE IMPACT OF ECONOMIC RECESSION	39
2.4	MARKET BREAKDOWN & DATA TRIANGULATION	40
FIGURE 8	MARKET DATA TRIANGULATION METHODOLOGY	40
2.5	MARKET SHARE ANALYSIS	41
2.6	STUDY ASSUMPTIONS	41
2.7	RESEARCH LIMITATIONS	41
2.7.1	METHODOLOGY-RELATED LIMITATIONS	41
2.8	RISK ASSESSMENT	41
TABLE 2	RISK ASSESSMENT: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET	41
3	EXECUTIVE SUMMARY	42
FIGURE 9	ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2023 VS. 2028 (USD MILLION)	42
FIGURE 10	ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)	43
FIGURE 11	ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)	43

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FIGURE 12	GEOGRAPHICAL SNAPSHOT OF ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET	44
4	PREMIUM INSIGHTS	45
4.1	ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET OVERVIEW	45
FIGURE 13	GROWING PREVALENCE OF INFECTIONS CAUSED BY DRUG-RESISTANT PATHOGENS TO DRIVE MARKET GROWTH	45
4.2	ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY REGION	46
FIGURE 14	ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD (2023-2028)	46
4.3	ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION AND COUNTRY (2022)	47
FIGURE 15	CLINICAL DIAGNOSTICS SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET IN 2022	47
4.4	ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: GEOGRAPHIC MIX	48
FIGURE 16	CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD	48
4.5	ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: DEVELOPED VS. EMERGING ECONOMIES	49
FIGURE 17	EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD	49
5	MARKET OVERVIEW	50
5.1	INTRODUCTION	50
FIGURE 18	ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	50
5.1.1	DRIVERS	50
5.1.1.1	Growing prevalence of infections caused by drug-resistant pathogens	50
5.1.1.2	Innovations in diagnostic technologies	51
5.1.1.3	Growing government initiatives to combat antimicrobial-resistant species	52
5.1.1.4	Emergence of multi-drug resistance due to drug abuse	52
5.1.2	RESTRAINTS	53
5.1.2.1	High cost of antimicrobial resistance diagnostic systems/kits	53
5.1.3	OPPORTUNITIES	53
5.1.3.1	Growth opportunities in emerging economies	53
5.1.3.2	Awareness initiatives for antimicrobial resistance and control	54
5.1.4	CHALLENGES	54
5.1.4.1	Complex regulatory frameworks	54
5.2	TECHNOLOGY ANALYSIS	55
5.2.1	REAL-TIME SURVEILLANCE PLATFORMS	55
5.2.2	CRISPR-CAS SYSTEMS	56
5.2.3	AI-POWERED MOBILE APPLICATIONS	56
5.3	PRICING ANALYSIS	57
5.3.1	AVERAGE SELLING PRICE TREND OF PRODUCTS OFFERED BY KEY PLAYERS	57
FIGURE 19	AVERAGE SELLING PRICE TREND OF PRODUCTS OFFERED BY KEY PLAYERS	57
TABLE 3	AVERAGE SELLING PRICE TREND OF PRODUCTS OFFERED BY KEY PLAYERS	57
5.3.2	AVERAGE SELLING PRICE TREND, BY REGION	58
TABLE 4	AVERAGE SELLING PRICE OF ANTIMICROBIAL RESISTANCE SURVEILLANCE SOLUTIONS, BY REGION	58
5.4	VALUE CHAIN ANALYSIS	58
FIGURE 20	ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: VALUE CHAIN ANALYSIS	58
5.5	SUPPLY CHAIN ANALYSIS	59
FIGURE 21	ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: SUPPLY CHAIN ANALYSIS	59
5.6	ECOSYSTEM ANALYSIS	60
FIGURE 22	ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: ECOSYSTEM MARKET MAP	60
5.7	PORTER'S FIVE FORCES ANALYSIS	60
TABLE 5	ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: PORTER'S FIVE FORCES ANALYSIS	60
5.7.1	THREAT OF NEW ENTRANTS	60

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.7.2	THREAT OF SUBSTITUTES	61
5.7.3	BARGAINING POWER OF BUYERS	61
5.7.4	BARGAINING POWER OF SUPPLIERS	61
5.7.5	INTENSITY OF COMPETITIVE RIVALRY	61
5.8	TARIFF AND REGULATORY ANALYSIS	61
5.8.1	TARIFF FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE DIAGNOSTIC SYSTEMS	61
TABLE 6 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS		
5.8.2	REGULATORY ANALYSIS	62
5.8.2.1	North America	62
5.8.2.1.1	US	62
TABLE 7 US FDA: MEDICAL DEVICE CLASSIFICATION		
TABLE 8 US: TIME, COST, AND COMPLEXITY OF REGISTRATION		
5.8.2.1.2	Canada	64
TABLE 9 CANADA: MEDICAL DEVICE CLASSIFICATION		
TABLE 10 CANADA: TIME, COST, AND COMPLEXITY OF REGISTRATION		
5.8.2.2	Europe	64
5.8.2.3	Asia Pacific	65
5.8.2.3.1	Japan	65
5.8.2.3.2	China	65
TABLE 11 CHINA: MEDICAL DEVICE CLASSIFICATION		
5.8.2.3.3	India	67
5.9	PATENT ANALYSIS	67
5.9.1	PATENT PUBLICATION TRENDS FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE PRODUCTS	67
FIGURE 23 PATENT PUBLICATION TRENDS (JANUARY 2011-AUGUST 2023)		
5.9.2	INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS	68
FIGURE 24 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE PATENTS (JANUARY 2011-AUGUST 2023)		
FIGURE 25 TOP APPLICANTS FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE PATENTS (COUNTRY/REGION) (JANUARY 2011-AUGUST 2023)		
TABLE 12 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: LIST OF PATENTS (2020-2023)		
5.10	KEY CONFERENCES & EVENTS IN 2023-2024	71
TABLE 13 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: DETAILED LIST OF CONFERENCES & EVENTS IN 2023-2024		
5.11	TRADE ANALYSIS	72
5.11.1	TRADE ANALYSIS FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE DIAGNOSTIC SYSTEMS	72
FIGURE 26 IMPORTS OF PRODUCTS UNDER HSN CODE: 90278090, BY COUNTRY, 2022 (USD THOUSAND)		
FIGURE 27 EXPORTS OF PRODUCTS UNDER HSN CODE: 90278090, BY COUNTRY, 2022 (USD THOUSAND)		
5.12	KEY STAKEHOLDERS & BUYING CRITERIA	73
5.12.1	KEY STAKEHOLDERS IN BUYING PROCESS	73
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ANTIMICROBIAL RESISTANCE SURVEILLANCE END USERS		
TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ANTIMICROBIAL RESISTANCE SURVEILLANCE END USERS (%)		
5.12.2	BUYING CRITERIA	74
FIGURE 29 KEY BUYING CRITERIA FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE END USERS		
TABLE 15 KEY BUYING CRITERIA FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE END USERS		
6 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION		
6.1	INTRODUCTION	76
TABLE 16 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION)		
6.2	DIAGNOSTIC KITS	76

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.2.1 RISING AWARENESS OF AMR TO DRIVE MARKET GROWTH 76

TABLE 17 DIAGNOSTIC KITS OFFERED BY KEY PLAYERS 77

TABLE 18 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR DIAGNOSTIC KITS, BY COUNTRY, 2021-2028 (USD MILLION) 77

6.3 DIAGNOSTIC SYSTEMS 78

6.3.1 GROWING THREAT OF ANTIBIOTIC RESISTANCE TO ACCELERATE MARKET GROWTH 78

TABLE 19 DIAGNOSTIC SYSTEMS OFFERED BY KEY PLAYERS 78

TABLE 20 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR DIAGNOSTIC SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION) 79

6.4 SURVEILLANCE & ANALYTICS SOFTWARE 79

6.4.1 TECHNOLOGICAL ADVANCEMENTS TO SUPPORT MARKET GROWTH 79

TABLE 21 SURVEILLANCE & ANALYTICS SOFTWARE OFFERED BY KEY PLAYERS 80

TABLE 22 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR SURVEILLANCE & ANALYTICS SOFTWARE, BY COUNTRY, 2021-2028 (USD MILLION) 80

6.5 OTHER SOLUTIONS 81

TABLE 23 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR OTHER SOLUTIONS, BY COUNTRY, 2021-2028 (USD MILLION) 81

7 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION 82

7.1 INTRODUCTION 83

TABLE 24 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 83

7.2 CLINICAL DIAGNOSTICS 83

7.2.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH 83

TABLE 25 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION) 84

7.3 PUBLIC HEALTH SURVEILLANCE 85

7.3.1 GOVERNMENT INITIATIVES TO ACCELERATE MARKET GROWTH 85

TABLE 26 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR PUBLIC HEALTH SURVEILLANCE, BY COUNTRY, 2021-2028 (USD MILLION) 85

7.4 OTHER APPLICATIONS 86

TABLE 27 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 86

8 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER 87

8.1 INTRODUCTION 88

TABLE 28 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION) 88

8.2 HOSPITALS & CLINICS 88

8.2.1 HIGH PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH 88

TABLE 29 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021-2028 (USD MILLION) 89

8.3 RESEARCH & ACADEMIC INSTITUTES 90

8.3.1 GROWING RESEARCH GRANTS AND FUNDING TO ACCELERATE MARKET GROWTH 90

TABLE 30 FUNDING BY DEPARTMENT OF HEALTH AND SOCIAL CARE (UK) FOR ANTIMICROBIAL RESISTANCE STUDIES, 2020 90

TABLE 31 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) 91

8.4 OTHER END USERS 91

TABLE 32 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION) 92

9 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY REGION 93

9.1 INTRODUCTION 94

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 33 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY REGION, 2021-2028 (USD MILLION) 94

9.2 NORTH AMERICA 94

FIGURE 30 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SNAPSHOT 95

TABLE 34 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 96

TABLE 35 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION) 96

TABLE 36 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 96

TABLE 37 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION) 97

9.2.1 US 97

9.2.1.1 US to dominate North American market during forecast period 97

TABLE 38 US: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION) 98

TABLE 39 US: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 98

TABLE 40 US: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION) 99

9.2.2 CANADA 99

9.2.2.1 Favorable government initiatives to drive growth during forecast period 99

TABLE 41 CANADA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION) 100

TABLE 42 CANADA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 100

TABLE 43 CANADA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION) 101

9.2.3 NORTH AMERICA: RECESSION IMPACT 101

9.3 EUROPE 101

TABLE 44 EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 102

TABLE 45 EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION) 102

TABLE 46 EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 103

TABLE 47 EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION) 103

9.3.1 GERMANY 103

9.3.1.1 Germany to dominate European market during forecast period 103

TABLE 48 GERMANY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION) 104

TABLE 49 GERMANY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 104

TABLE 50 GERMANY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION) 105

9.3.2 UK 105

9.3.2.1 Significant prevalence of infectious diseases coupled with increasing awareness to drive market growth 105

TABLE 51 UK: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION) 106

TABLE 52 UK: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 106

TABLE 53 UK: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION) 107

9.3.3 FRANCE 107

9.3.3.1 Supportive government policies and easy accessibility to healthcare services to fuel growth 107

TABLE 54 FRANCE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION) 108

TABLE 55 FRANCE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 108

TABLE 56 FRANCE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION) 109

9.3.4 ITALY 109

9.3.4.1 Increasing R&D investments by pharmaceutical companies to propel demand 109

TABLE 57 ITALY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION) 110

TABLE 58 ITALY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 110

TABLE 59 ITALY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION) 111

9.3.5 SPAIN 111

9.3.5.1 Rising geriatric population to drive market growth 111

TABLE 60 SPAIN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION) 112

TABLE 61 SPAIN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 112

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 62 □ SPAIN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION) □ 113

9.3.6 □ REST OF EUROPE □ 113

TABLE 63 □ REST OF EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION) □ 113

TABLE 64 □ REST OF EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) □ 114

TABLE 65 □ REST OF EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION) □ 114

9.3.7 □ EUROPE: RECESSION IMPACT □ 114

9.4 □ ASIA PACIFIC □ 115

FIGURE 31 □ ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SNAPSHOT □ 116

TABLE 66 □ ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 117

TABLE 67 □ ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION) □ 117

TABLE 68 □ ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) □ 118

TABLE 69 □ ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION) □ 118

9.4.1 □ JAPAN □ 118

9.4.1.1 □ Growing geriatric population to drive market □ 118

TABLE 70 □ JAPAN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION) □ 119

TABLE 71 □ JAPAN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) □ 119

TABLE 72 □ JAPAN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION) □ 120

9.4.2 □ CHINA □ 120

9.4.2.1 □ Favorable government regulations and heavy burden of infectious diseases to drive market growth □ 120

TABLE 73 □ INCIDENCE OF INFECTIOUS DISEASES IN CHINA, 2020 □ 120

TABLE 74 □ CHINA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION) □ 121

TABLE 75 □ CHINA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) □ 121

TABLE 76 □ CHINA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION) □ 122

9.4.3 □ INDIA □ 122

9.4.3.1 □ Growing initiatives for clinical diagnosis by government and major players to drive market growth □ 122

TABLE 77 □ INDIA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION) □ 123

TABLE 78 □ INDIA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) □ 123

TABLE 79 □ INDIA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION) □ 124

9.4.4 □ REST OF ASIA PACIFIC □ 124

TABLE 80 □ REST OF ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION) □ 124

TABLE 81 □ REST OF ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) □ 125

TABLE 82 □ REST OF ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION) □ 125

9.4.5 □ ASIA PACIFIC: RECESSION IMPACT □ 125

9.5 □ LATIN AMERICA □ 126

9.5.1 □ GROWING ECONOMIC DEVELOPMENT TO DRIVE MARKET GROWTH □ 126

9.5.2 □ LATIN AMERICA: RECESSION IMPACT □ 126

TABLE 83 □ LATIN AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION) □ 126

TABLE 84 □ LATIN AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) □ 127

TABLE 85 □ LATIN AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION) □ 127

9.6 □ MIDDLE EAST & AFRICA □ 127

9.6.1 □ GROWING INCIDENCE OF INFECTIOUS DISEASES AND LARGE PATIENT POOL TO DRIVE MARKET GROWTH □ 127

9.6.2 □ MIDDLE EAST & AFRICA: RECESSION IMPACT □ 128

TABLE 86 □ MIDDLE EAST & AFRICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021-2028 (USD MILLION) □ 128

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 87	MIDDLE EAST & AFRICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	128
TABLE 88	MIDDLE EAST & AFRICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021-2028 (USD MILLION)	129
10	COMPETITIVE LANDSCAPE	130
10.1	INTRODUCTION	130
10.2	STRATEGIES ADOPTED BY KEY PLAYERS	130
TABLE 89	OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET	131
10.3	REVENUE SHARE ANALYSIS	132
FIGURE 32	REVENUE ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET (2018-2022)	132
10.4	MARKET SHARE ANALYSIS	132
FIGURE 33	MARKET SHARE ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET (2022)	133
10.5	COMPANY EVALUATION MATRIX FOR MAJOR PLAYERS (2022)	134
10.5.1	STARS	134
10.5.2	EMERGING LEADERS	135
10.5.3	PERVASIVE PLAYERS	135
10.5.4	PARTICIPANTS	135
FIGURE 34	ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022	135
10.5.5	COMPANY FOOTPRINT	136
TABLE 90	COMPANY FOOTPRINT ANALYSIS, BY SOLUTION	136
TABLE 91	COMPANY FOOTPRINT ANALYSIS, BY APPLICATION	137
TABLE 92	COMPANY FOOTPRINT ANALYSIS, BY END USER	138
TABLE 93	COMPANY FOOTPRINT ANALYSIS, BY REGION	139
10.6	COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2022)	140
10.6.1	PROGRESSIVE COMPANIES	140
10.6.2	RESPONSIVE COMPANIES	140
10.6.3	DYNAMIC COMPANIES	140
10.6.4	STARTING BLOCKS	140
FIGURE 35	ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: COMPANY EVALUATION MATRIX FOR SMES/START-UPS, 2022	141
10.6.5	COMPETITIVE BENCHMARKING	141
TABLE 94	ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: COMPANY FOOTPRINT OF KEY PLAYERS	141
10.7	COMPETITIVE SCENARIO	142
10.7.1	PRODUCT LAUNCHES	142
TABLE 95	ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2020-SEPTEMBER 2023	143
10.7.2	DEALS	144
TABLE 96	ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: DEALS, JANUARY 2020-SEPTEMBER 2023	144
11	COMPANY PROFILES	145
11.1	KEY PLAYERS	145
	(Business overview, Products offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses & Competitive threats)*	
11.1.1	BIOMERIEUX SA	145
TABLE 97	BIOMERIEUX SA: BUSINESS OVERVIEW	145
FIGURE 36	BIOMERIEUX SA: COMPANY SNAPSHOT (2022)	146
11.1.2	THERMO FISHER SCIENTIFIC INC.	150
TABLE 98	THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW	150
FIGURE 37	THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)	151

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.1.3	BECTON, DICKINSON AND COMPANY	154
TABLE 99	BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW	154
FIGURE 38	BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)	155
11.1.4	DANAHER CORPORATION	158
TABLE 100	DANAHER CORPORATION: BUSINESS OVERVIEW	158
FIGURE 39	DANAHER CORPORATION: COMPANY SNAPSHOT (2022)	159
11.1.5	BIO-RAD LABORATORIES, INC.	162
TABLE 101	BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW	162
FIGURE 40	BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)	163
11.1.6	LUMINEX CORPORATION	165
TABLE 102	LUMINEX CORPORATION: BUSINESS OVERVIEW	165
FIGURE 41	LUMINEX CORPORATION: COMPANY SNAPSHOT (2022)	165
11.1.7	BRUKER CORPORATION	167
TABLE 103	BRUKER CORPORATION: BUSINESS OVERVIEW	167
FIGURE 42	BRUKER CORPORATION: COMPANY SNAPSHOT (2022)	168
11.1.8	ROCHE DIAGNOSTICS (A DIVISION OF F-HOFFMAN-LA ROCHE LTD.)	170
TABLE 104	ROCHE DIAGNOSTICS: BUSINESS OVERVIEW	170
FIGURE 43	ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2022)	171
11.1.9	T2 BIOSYSTEMS, INC.	173
TABLE 105	T2 BIOSYSTEMS, INC.: BUSINESS OVERVIEW	173
FIGURE 44	T2 BIOSYSTEMS, INC.: COMPANY SNAPSHOT (2022)	173
11.1.10	MERCK KGAA	175
TABLE 106	MERCK KGAA: BUSINESS OVERVIEW	175
FIGURE 45	MERCK KGAA: COMPANY SNAPSHOT (2022)	176
11.1.11	ACCELERATE DIAGNOSTICS, INC.	178
TABLE 107	ACCELERATE DIAGNOSTICS, INC.: BUSINESS OVERVIEW	178
FIGURE 46	ACCELERATE DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2022)	178
11.1.12	BIOANALYSE	180
TABLE 108	BIOANALYSE: BUSINESS OVERVIEW	180
11.1.13	HIMEDIA LABORATORIES	181
TABLE 109	HIMEDIA LABORATORIES: BUSINESS OVERVIEW	181
11.1.14	LIOFILCHEM S.R.L.	183
TABLE 110	LIOFILCHEM S.R.L.: BUSINESS OVERVIEW	183
11.1.15	ALIFAX S.R.L.	186
TABLE 111	ALIFAX S.R.L.: BUSINESS OVERVIEW	186
11.1.16	WOLTERS KLUWER N.V.	188
TABLE 112	WOLTERS KLUWER N.V.: BUSINESS OVERVIEW	188
FIGURE 47	WOLTERS KLUWER N.V.: COMPANY SNAPSHOT (2022)	189
11.1.17	OPGEN, INC.	190
TABLE 113	OPGEN, INC.: BUSINESS OVERVIEW	190
FIGURE 48	OPGEN, INC.: COMPANY SNAPSHOT (2022)	190
11.1.18	CREATIVE DIAGNOSTICS	192
TABLE 114	CREATIVE DIAGNOSTICS: BUSINESS OVERVIEW	192
11.1.19	SYNBIOSIS	194
TABLE 115	SYNBIOSIS: BUSINESS OVERVIEW	194
11.2	OTHER PLAYERS	195
11.2.1	ZHUHAI DL BIOTECH CO., LTD.	195

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.2.2 ELITECHGROUP 195

11.2.3 MAST GROUP LTD. 196

11.2.4 CONDALAB 196

11.2.5 GENEFLUIDICS, INC. 197

11.2.6 MP BIOMEDICALS 197

*Details on Business overview, Products offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses & Competitive threats might not be captured in case of unlisted companies.

12 APPENDIX 198

12.1 DISCUSSION GUIDE 198

12.2 KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL 201

12.3 CUSTOMIZATION OPTIONS 203

12.4 RELATED REPORTS 203

12.5 AUTHOR DETAILS 204

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Antimicrobial Resistance Surveillance Market by Solution (Kits, System, Surveillance Software, Service), Application (Clinical Diagnostics, Public Health Surveillance), End User (Hospitals, Clinics, Academic, Research Institutes) - Global Forecast to 2028

Market Report | 2023-09-19 | 200 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2026-03-03

Signature

A large, empty rectangular box intended for a signature.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com